Innovating Works

INN-TIME

Financiado
Co-option of host circadian rhythms in cancer
Circadian rhythms (CRs) are the biological response to the periodic rotations of the Earth, and allow fundamental adaptations of organisms to a changing environment. CRs are molecularly controlled in every cell by a set of transcr... Circadian rhythms (CRs) are the biological response to the periodic rotations of the Earth, and allow fundamental adaptations of organisms to a changing environment. CRs are molecularly controlled in every cell by a set of transcriptional factors that control, and are influenced by, core biological processes including metabolic, immune, and proliferative. My previous studies established, for the first time, that innate immune cells regulate the circadian physiology of tissues, including the susceptibility of the lung to be metastasized. In INN-TIME, I ask the reciprocal question to reveal if tumors take advantage of, and subvert, CRs of the innate (immune and stroma) compartments to escape anti-tumoral defense. INN-TIME Aims to understand how oncogenic processes rewire CRs of the host and to elucidate strategies that halt this subversion as a new approach to fight cancer. Using lung cancer as proof-of-principle, I will first investigate cell-intrinsic circadian programs in tumors (Aim1). Next, I will define how tumors co-opt circadian clocks of the host and explore how the molecular clock of innate immune (Aim2) and supporting stromal cells (Aim3) impacts tumor growth, both molecularly and functionally. By integrating multiple transcriptomics and functional approaches, INN-TIME will discover novel regulatory programs in tumors using a circadian approach, and pave the way to design strategies to prevent cancer by interfering with tumor-supportive circadian programs. INN-TIME will revolutionize the way we understand cancer, as it will identify the malignant roots of circadian rhythms and their impact on host defense. This research will establish a new paradigm by revealing the mechanisms underlying pro-tumorigenic clocks, and will provide robust foundations for new therapies in a set of disorders in which circadian clock (dys)functions are implicated. ver más
28/02/2029
2M€
Duración del proyecto: 62 meses Fecha Inicio: 2023-12-15
Fecha Fin: 2029-02-28

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-15
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG: ERC STARTING GRANTS
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5 18M